Urothelial cancers and their genetic roots traditionally have been understudied, and treatments for these cancers are
Potential New Treatments for Bladder Cancer
December 10, 2020
A significant percentage of patients with urothelial cancers have inherited gene variants that drive the progression of these cancers, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.
EIPM Leads Scalable Clinical WGS Initiative
December 3, 2020
Seeking to advance the scope of precision medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina, Inc. are entering into a collaboration to sequence the complete human genomes of thousands of consenting patients, in order to identify genetic alterations driving disease and potentially reveal previously unidentified therapies for treatment.
Esophageal Cancer Survival Extended
December 2, 2020
The immunotherapy drug pembrolizumab, known by its brand name Keytruda, is a safe and effective option for patients with locally advanced and metastatic squamous cell esophageal cancer who have already received standard chemotherapy, according to a new study co-authored by a Weill Cornell Medicine and NewYork-Presbyterian investigator. The study reports results of a phase 3 clinical trial in which Weill Cornell Medicine, with NewYork-Presbyterian, was a lead site.
December 2020 EIPM Director’s Memo
December 1, 2020
December 01, 2020
Dear Members of the Englander Institute,
The past year will be remembered for the heroic response by the medical community to treat Covid-19 patients, and by the investigators who developed effective treatments and vaccines with amazing speed and precision.
We have a lot to be thankful for despite the pandemic’s deadly impact. I’m especially thankful for the hardwork and dedication of our EIPM and Weill Cornell Medicine colleagues who met these challenges head-on as the virus tore through New York City in the early days of the pandemic.
EIPM Embraces Entrepreneurship
November 5, 2020
EIPM to Study Cancer Genetics Among Underserved
October 16, 2020
Drawing on New York’s diverse population, Weill Cornell Medicine scientists have been awarded grants from the New York Genome Center (NYGC) to study how several types of cancer differ in patients with different genetic backgrounds and point to precision treatments for groups that have been historically underrepresented in cancer research.
EIPM Studies Outcomes in Cancer Patients with COVID-19
October 16, 2020
Cancer patients who contracted COVID-19 during the height of the pandemic in New York City had similar outcomes to other patients with COVID-19, a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian has found. The findings suggest that in the absence of other risk factors for poor COVID-19 outcomes, patients with cancer may be able to safely continue treatment during the pandemic.
New Study Examines Mysteries of COVID-19
October 12, 2020
A study by investigators at Weill Cornell Medicine and NewYork-Presbyterian aims to answer one of COVID-19’s biggest mysteries: why do some people become severely ill, while others have no symptoms? The multidisciplinary team will seek to identify underlying genetic and immune factors that contribute to these varying outcomes to help guide the development of precision prevention and treatment efforts.
EIPM October 2020 External Newsletter
October 6, 2020
The EIPM External Newsletter below is sent quarterly to people who sign-up on our website.
Dear Friends of the EIPM:
During these extraordinary times we have continued to create breakthroughs in basic research that will benefit patients with cancer, metabolic disease, neurologic impairments, and many more conditions. Our researchers have also worked collaboratively with investigators across the country and around the world to unlock the mysteries of Covid-19, and contribute to new treatments and therapies for patients.
How Tumors Extensively Rewrite Their DNA
October 5, 2020
Cancer cells rearrange, copy, and delete their DNA in complex but distinct patterns, according to new research from a multi-institution team led by investigators at Weill Cornell Medicine and the New York Genome Center. The investigators developed sophisticated new algorithms to analyze nearly 3,000 genome sequences from human tumors.